Replies to post #26417 on 22nd Century Group Inc (XXII)

[MinnieM]

Couldn't disagree with you more about timing of removal. The sooner he was removed, the better. He may have started out fine, but, he ended up a major louse.

Good luck all, I'm out the door.

[Atlanta1]

ROFLMFAO

$XXII is providing an increasingly positive stream of news.

My view is to the future, which is very bright.

[ChairmanoftheBored]

My two cents:

IMO it was JP's actions that forced the Board's hand towards his removal as CEO. BOD could not control the timing of that. I never thought JP was fit to be CEO In the first place, and between him "leading investors on" and making stock transactions against Counsel's recommendation, I'm glad the BOD (with Big Tobacco experience) took the action they did.
[Quote]
"Removing the CEO JP at a very critical time in the young life of this upstart XXII was not the most advantageous course to take by the BOD. With the s/p of XXII down 71%, how can anyone state that removing JP was a good thing?"


We have one Q of meaningful commercial product revenue and the number of RED SUN locations is already expected to quadruple from Q1. Too early to make a call in regards to launch at this point.
[Quote]
"All one has to do is view the Red Sun area of the XXII website and see the lame attempt in the early promotion of red sun by what appeared to be amateurs at best! "

The European machines had to retest XXII's low nicotine tobacco for labeling purposes and Magic was launched very close to when it was expected to be.
[Quote]
"Magic didn't get released in the EU until recently.
And who will take responsibility for the delay?"

Clinical studies vary wildly depending on specific study but in many studies it has been the FDA/NIH buying cigarettes from XXII (since they have a virtual monopoly around VLNC and low-tar yield). Asian details were covered in the Q1 CC.
[Quote]
Does anyone know exactly what is involved in the lengthy and very costly endeavor in the process of clinical studies? Where is the FAR EAST (Japan-China CNTC) deals that have been touted for some time after bringing TP with his connection on board to promote XXII's products. The silence is deafening

Again IMO it was JP's actions that forced the BOD to make a change, timing was not a controlled variable.
[Quote]
"The above needs no other comments other than the timing of this coup could not have come at a worse time in the young upstart life of XXII. Nothing like having a lynching of the CEO by keeping him and all investors hanging in the wind post "

150% sales increase (expected minimum) could certainly go a long way.
[Quote]
"Let us all hope that the revenue stream from sales will increase dramatically from the previous quarter."